Associated Papers
Improvement of Diagnostics in NSCLC Patients with MET Exon 14 Mutations Using Complementary DNA/RNA-NGS and Identification of Two Novel Exonic Splicing Mutations.
Urbanska EM et al.
International Journal of Molecular Sciences, 2025
Discovery of Novel RASGRF2 Fusions as a Therapeutic Target in Lung Adenocarcinoma of Never or Light Smokers.
Terashima Y et al.
Cancer Science, 2025
40734624 (PubMed )
Supplement: CAS-116-2868-s002.xlsx › Table_S3
Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration.
Feng H et al.
Cancer Biology & Medicine, 2025
40200811 (PubMed )
Supplement: cbm-22-237-s001.pdf
Chinese expert consensus on clinical practice of MET detection in non-small cell lung cancer.
Bai Q et al.
Therapeutic Advances in Medical Oncology, 2024
Optimized Detection of Unknown MET Exon 14 Skipping Mutations in Routine Testing for Patients With Non-Small-Cell Lung Cancer.
Sun R et al.
Jco Precision Oncology, 2023
Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology.
Adib E et al.
Genome Medicine, 2022
35428358 (PubMed )
Supplement: 13073_2022_1041_MOESM2_ESM.xlsx › S4_MET_Druggable
Mesenchymal-Epithelial Transition Exon 14 Skipping Mutation and Amplification in 5,008 Patients With Lung Cancer.
Song Y et al.
Frontiers in Oncology, 2021
Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancers.
Yang H et al.
Lung Cancer (amsterdam, Netherlands), 2020
Select a paper to view details